NSABP MEMBER: MICHIGAN STATE UNIVERSITY

密歇根州立大学癌症联盟（MSUCTC）由密歇根州立大学的社区校园组成，沿着全州的社区癌症项目，并在密歇根州立大学的主校区进行领导和协调。 MSUCTC目前正在治疗和随访1，105名长期NSABP方案的患者。 方案应计费用将通过四种机制继续增加：1）增加对目前活跃的社区肿瘤学家的科学和后勤支持; 2）为MSUCTC招募更多的肿瘤学家和外科医生。 我们的行政工作将集中在：1）增加主校区NSABP工作人员在我们广泛分散的社区活动中的存在（例如，肿瘤委员会、大查房、医生和护理研讨会等）; 2)通过增加当地审计来支持临床试验基础设施，以消除方案违反和减少拖欠; 3）为密歇根州立大学附属机构开发一个具体的NSABP网站; 4）参与试点研究项目; 5）与以往一样，我们小组将继续广泛参与NSABP活动（PI董事会成员，乳腺委员会，结肠委员会，方案设计组，稽查组，护理委员会。MSUCTC一直关注生活质量问题，因此，我们的计划是设计一项辅助治疗的认知影响的初步研究，该研究将作为更大的NSABP试验的模型。 此外，我们将在密歇根州的美洲原住民社区进行一项关于接受和遵守NSABP协议的研究，这将有助于该集团设计一项战略，以实现这一人口的增长。 我们的机构有一个特殊的计划，以促进和监测少数民族的累积NSABP试验由NIH补充赠款支持。 这一经验将转达给国家生物多样性战略规划局。我们拥有一个完善的实验室，配备了HPLC，GLC和质谱仪器，我们的机构将为该集团提供与药物和激素代谢物相关的其他研究。最近，密歇根州立大学已经形成了一个强大的小组开发靶向治疗。 我们已经检测到化疗期间MAP激酶的实质性变化（包括使用替代组织），这将作为NSABP方案执行期间设计试点研究的基础。 我们正在为方案B-30的患者准备一份试点方案，该方案将提交给NSABP批准。 密歇根州立大学的一个跨学科小组正在研究细胞周期调控基因和基因产物的相互关系和异常，以及它们对肿瘤从非侵袭性（DCIS）发展到侵袭性和转移性疾病的影响。 这可能有助于预测生物学行为以及治疗反应。 这两个研究领域相互补充，可能有助于该小组设计具有药物基因组学元素的方案。

The Michigan State University Cancer Consortium (MSUCTC) consists of the community campuses of MSU along with community cancer programs across the state, with leadership and coordination at the main MSU campus. The MSUCTC is currently treating and following 1,105 patients on long-term NSABP protocols. Accrual to protocols will continue to increase by four mechanisms: 1) Increasing the scientific and logistic support for currently active community oncologists; and 2) Recruitment of additional oncologists and surgeons to the MSUCTC. Our administrative efforts will focus on: 1) Increasing the presence of the main campus NSABP staff in the activities of our widely dispersed communities (e.g., tumor boards, grand rounds, physicians and nursing seminars, etc.); 2) Clinical trials infrastructural support by increasing local audits in order to eliminate protocol violations and decrease delinquencies; 3) Development of a specific NSABP web site for MSU affiliates; 4) Participation in pilot research projects; 5) As in the past, our group will continue to participate extensively in the NSABP activities (PI member of the board, breast committee, colon committee, protocol design group, audit group, and nursing committee. The MSUCTC has been concerned about quality of life issues, therefore, our plans are to design a pilot study of the cognitive effects of adjuvant therapy which will serve as a model for a larger NSABP trial. In addition, we will be conducting a study of acceptance and compliance with NSABP protocols in Native American communities in Michigan which will help the group design a strategy for approach to accrual of this population. Our institution has a special program to foster and monitor accrual of ethnic minorities to NSABP trials supported by NIH supplemental grants. This experience will be conveyed to the NSABP. Having a well-developed laboratory, equipped with HPLC, GLC, and Mass Spectroscopy apparatuses, our institution will offer to the group additional studies related to drug and hormone metabolites. Recently, MSU has formed a strong group developing targeted therapy. We have detected substantial changes in MAP-kinases during chemotherapy (including use of surrogate tissues) which will serve as a basis for designing pilot studies during the execution of NSABP protocols. We are in the process of preparation of a pilot protocol with patients on protocol B-30 which will be submitted to the NSABP for approval. An interdisciplinary group at MSU is studying the interrelations and abberations of cell cycle regulatory genes and gene products and their effect on tumor progression from non-invasive (DCIS) to invasive and metastatic disease. This may help to predict biologic behavior as well as treatment response. These two areas of research complement each other and may help the group design protocols with pharmacogenomic elements.